Skip to main content
Blog

Longitudinal biospecimen & data collections

By August 30, 2021August 31st, 2021No Comments

Are you looking to study how biomarker levels change in blood, tissue, and other biospecimens throughout the course of a disease?  Perhaps you’d like to simultaneously understand symptom progression and co-morbidity development?  Perhaps look at therapeutic response or survival?

The MT Group has longitudinally collected biospecimens for pharmaceutical R&D from thousands of subjects, regularly achieving a 95%+ retention rate for those enrolled.

Many Studies Are Possible:

  •   Solid tumors, heme malignancies, inflammatory bowel disease, autoimmune disease, COVID-19, NASH, at-risk, healthy, and other populations
  •   Blood, plasma, serum, saliva, urine, buccal swabs, and tissue
  •   Comprehensive clinical metadata including medical history, symptoms and severity, co-morbidities, lifestyle, therapies, outcomes, and demographics
  •   Collections pre-diagnosis, at diagnosis, on first line therapy, on later therapies, and at relapse